1-9 of 9
Christian Maurer
Close
Sort by
Journal Articles

Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG)

Moritz Fürstenau, MD, Georg Hopfinger, MD, Sandra Robrecht, PhD, Anna-Maria Fink, MD, Othman Al-Sawaf, MD, Petra Langerbeins, MD, Paula Cramer, Julia Von Tresckow, MD, Christian Maurer, MD, Nadine Kutsch, MD, Manuela Hoechstetter, MD, Martin Dreyling, MD PhD, Elisabeth Lange, Michael Kneba, Stephan Stilgenbauer, MD PhD, Hartmut Döhner, MD, Manfred Hensel, MD, Michael G. Kiehl, MD PhD, Ulrich Jaeger, MD, Clemens-Martin Wendtner, Valentin Goede, MD, Kirsten Fischer, MD, Michael Hallek, Barbara Eichhorst, Sebastian Theurich, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4429.
https://doi.org/10.1182/blood-2018-99-113257
Published: 2018
Journal Articles

Prognostic Impact of Immunohistochemistry and MRD Results in Bone Marrow after Frontline Chemoimmunotherapy of Chronic Lymphocytic Leukemia (CLL): Results of Central Laboratory Analyses of the CLL10 Trial of the German CLL Study Group (GCLLSG)

Nadine Kutsch, MD, Sebastian Böttcher, MD PhD, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Christian Maurer, MD, Elisabeth Lange, MD, Hubert Köppler, MD, Michael G Kiehl, MD, Martin Sökler, MD, Rudolf Schlag, MD, Ursula Vehling-Kaiser, MD, Georg Köchling, MD, Christoph Plöger, MD, Michael Gregor, MD, Torben Plesner, MD, Ilske Oschlies, MD, Marco Herling, MD PhD, Kirsten Fischer, MD, Hartmut Döhner, MD, Michael Kneba, MD, Clemens-Martin Wendtner, MD, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD PhD, Anna Maria Fink, MD, Michael Hallek, MD, Wolfram Klapper, MD, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3021.
https://doi.org/10.1182/blood.V130.Suppl_1.3021.3021
Published: 2017
Journal Articles

Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara F. Eichhorst, MD, Jasmin Bahlo, Christian Maurer, MD, Elisabeth Lange, MD, Hubert Köppler, Prof., Michael G Kiehl, MD, Martin Sökler, MD, Rudolf Schlag, Ursula Vehling-Kaiser, MD, Georg Köchling, MD, Christoph Plöger, MD, Michael Gregor, Torben Plesner, MD, Marco Herling, MD PhD, Kirsten Fischer, Hartmut Döhner, MD, Michael Kneba, Clemens Wendtner, MD, Wolfram Klapper, MD, Karl-Anton Kreuzer, Sebastian Böttcher, Stephan Stilgenbauer, Anna Maria Fink, MD, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 4382.
https://doi.org/10.1182/blood.V128.22.4382.4382
Published: 2016
Journal Articles

Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG)

Othman Al-Sawaf, MD, Sandra Robrecht, Jasmin Bahlo, Anna Maria Fink, MD, Paula Cramer, MD, Christian Maurer, MD, Manuela A. Bergmann, MD, Martin H. Dreyling, MD PhD, Elisabeth Lange, MD, Michael Kneba, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Michael G Kiehl, MD, Ulrich Jäger, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, Michael Hallek, Barbara F. Eichhorst, MD, Georg Hopfinger, MD
Journal: Blood
Blood (2016) 128 (22): 4394.
https://doi.org/10.1182/blood.V128.22.4394.4394
Published: 2016
Journal Articles

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

Clinical Trials & Observations
Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink, Valentin Goede, Carmen Diana Herling, Paula Cramer, Petra Langerbeins, Julia von Tresckow, Anja Engelke, Christian Maurer, Gabor Kovacs, Marco Herling, Eugen Tausch, Karl-Anton Kreuzer, Barbara Eichhorst, Sebastian Böttcher, John F. Seymour, Paolo Ghia, Paula Marlton, Michael Kneba, Clemens-Martin Wendtner, Hartmut Döhner, Stephan Stilgenbauer, Michael Hallek
Journal: Blood
Blood (2016) 127 (2): 208–215.
https://doi.org/10.1182/blood-2015-06-651125
Published: 2016
Includes: Supplemental data
Journal Articles

Prognostic Impact and Risk Factors of Reducing Prescribed Doses of Fludarabine, Cyclophosphamide and Rituximab (FCR) during Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

Gabor Kovacs, MD, Jasmin Bahlo, Sandra Kluth, Paula Cramer, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Carolin Gross-Ophoff-Mueller, MD, Petra Langerbeins, MD, Christian Maurer, MD, Julia von Tresckow, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Michael Hallek, MD, Barbara Eichhorst, MD, Valentin Goede, MD
Journal: Blood
Blood (2015) 126 (23): 4156.
https://doi.org/10.1182/blood.V126.23.4156.4156
Published: 2015
Journal Articles

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara Eichhorst, MD, Anna Maria Fink, MD, Raymonde Busch, Gabor Kovacs, MD, Christian Maurer, MD, Elisabeth Lange, MD, Hubert Köppler, Prof. Dr., Michael G Kiehl, MD, Martin Soekler, MD, Rudolf Schlag, Ursula Vehling-Kaiser, MD, Georg R.A. Köchling, MD, Christoph Plöger, MD, Michael Gregor, MD, Torben Plesner, MD, Marek Trneny, MD, Kirsten Fischer, Hartmut Döhner, MD, Michael Kneba, MD PhD, Clemens-Martin Wendtner, MD, Wolfram Klapper, MD, Karl Anton Kreuzer, Prof. Dr. MD, Stephan Stilgenbauer, MD PhD, Sebastian Böttcher, MD, Michael Hallek, MD
Journal: Blood
Blood (2014) 124 (21): 19.
https://doi.org/10.1182/blood.V124.21.19.19
Published: 2014
Journal Articles

Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG)

Gabor Kovacs, MD, Sebastian Boettcher, MD, Jasmin Bahlo, Sandra Kluth, Dr., Matthias Ritgen, Anna Maria Fink, MD, Irene Stodden, Paula Cramer, MD, Julia von Tresckow, MD, Christian Maurer, MD, Hartmut Doehner, Prof., Stephan Stilgenbauer, MD, Michael Kneba, MD PhD, Kirsten Fischer, Michael Hallek, MD, Barbara Eichhorst, MD
Journal: Blood
Blood (2014) 124 (21): 23.
https://doi.org/10.1182/blood.V124.21.23.23
Published: 2014
Journal Articles

Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen

Kirsten Fischer, MD, Jasmin Bahlo, Anna- Maria Fink, MD, Raymonde Busch, Sebastian Böttcher, MD, Jiri Mayer, MD, Peter Dreger, MD, Christian Maurer, Anja Engelke, Michael Kneba, MD, PhD, Hartmut Döhner, MD, Barbara F. Eichhorst, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Michael Hallek, MD
Journal: Blood
Blood (2012) 120 (21): 435.
https://doi.org/10.1182/blood.V120.21.435.435
Published: 2012